Business Wire

VERTIGIS

10.3.2022 07:02:11 CET | Business Wire | Pressemeddelelse

Del
EDP sluttes sammen med VertigGIS og åbner nordisk marked

VertigGIS, en førende udbyder og softwareudvikler af geografiske informationssystemer (GIS), har gennemført erhvervelsen af 100 % af EDP Consult AB, en etableret leverandør af software og services med base i Staffanstorp i Sverige.

Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20220309005032/da/

VertiGIS støttes af et globalt investeringsselskab med fokus på teknologi, Battery Ventures, der i 2017 begyndte at erhverve softwarevirksomheder inden for GIS- og positionsteknologi under sit varemærke.

EDP, der er bedst kendt for produkterne EDP Future, EDP Mobile og EDP Vision, udvikler og leverer software til svenske kommuner. Virksomhedens teknologi håndterer specifikt kundens udfordringer inden for vand og affald, fjernvarme, leje og generel fakturering samt sagsovervågning og dokumentstyring for alle dele af den offentlige administration, offentlige styrelser og virksomheder.

EDP's stifter og administrerende direktør Mikael Nyquist forklarer: "Jeg er stolt over det, som mine EDP-kolleger har opnået i løbet af de seneste 39 år, og jeg er spændt på at se, hvordan vi vil udvikle os og tilbyde vores kunder ny værdi som en del af VertiGIS."

EDP bliver partner i VertiGIS' eksisterende virksomhed inden for den offentlige sektor, der har årtiers dokumenteret ekspertise i at hjælpe kommuner med at løse lignende udfordringer på dets respektive markeder.

"EDP's kundeorienterede tilgang til digitalisering af processer og løsning af udfordringer med positionsteknologi passer godt til vores," tilføjer Richard Wiegmann, President & CEO for VertigGIS. "Vi er glade for at få EDP med i VertiGIS og ser frem til at være med til at tilbyde deres ekspertise til nye kunder over hele verden, samtidig med at vi finder muligheder for eksisterende VertiGIS-teknologi på det nordiske marked."

EDP's produktlinjer slås sammen med VertiGIS’ løsninger til offentlig sektor- og arealforvaltning, forsyning og energi, telekommunikation og infrastruktur- og ejendomsadministration, der betjener mere end 5.200 kunder over hele verden.

Om VertiGIS:

VertiGIS er førende udbyder og softwareudvikler inden for geografiske informationssystemer (GIS). Virksomheden har fokus på udvikling af softwareløsninger og tjenester, der hjælper kunder inden for forsyning og energi, arealforvaltning, den offentlige sektor, telekommunikation samt branchekunder med at koble deres forretningsprocesser sammen med positionsteknologi. Produktporteføljen fra VertiGIS anvendes af tusindvis af kunder og millioner af slutbrugere i over 50 lande og er designet til at forbedre egenskaberne ved førende kortlægningssoftware, især ESRI's ArcGIS®. De vigtigste produktmærker omfatter: VertiGIS Studio, UT for ArcGIS®, 3A produktlinjen, GEONIS, ConnectMaster™, M4® Solutions, GeoOffice, WebOffice, ProOffice og EDP-produkterne Future, Mobile og Vision. Få mere at vide påwww.vertigis.com .

Om EDP:

Mere end 90 % af Sveriges kommuner driver deres daglige virksomhed ved hjælp af software fra EDP. Ved at arbejde tæt sammen med svenske kommuner, statslige styrelser og store virksomheder udvikler EDP sammenhængende, funktionelle og tidsbesparende IT-løsninger til den offentlige sektor. EDP-software anvendes på flere forskellige forretningsområder, f.eks. affaldshåndtering og styring af byggetilladelser, og bidrager til et velfungerende digitalt samfund, der er tilgængeligt for alle. Få mere at vide på www.edp.se .

Om Battery Ventures:

Battery bidrager med exceptionelle stiftere og ledelsesteams og udvikler kategoridefinerende virksomheder på markeder såsom software og services, virksomhedsinfrastruktur, onlinemarkeder, sundheds-IT og industriteknologi. Virksomheden blev stiftet i 1983 og støtter virksomheder på alle stadier, lige fra seed-kapital og tidligt i processen til vækst og overtagelse, og investerer globalt fra kontorer i Boston, San Francisco og Menlo Park, Californien, Herzliya, Israel; London og New York. Følg firmaet på Twitter @BatteryVentures, besøg vores hjemmeside på www.battery.com , og se en komplet liste over selskaberne i Batterys portefølje her .

Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.

Link:

ClickThru

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye